Millipore expands drug development facilties
This article was originally published in Scrip
Millipore, a US-based biopharmaceutical manufacturing company, will expand its drug discovery facility in St Charles, Missouri. The $3.4 million expansion will see the company hire an additional 60 employees to add to the 187 that already work at the St Charles facility. Millipore is seeking certification from the Leadership in Energy and Environmental Design (LEED) green building rating system for the expanded 17,000sq ft space, where it will build new laboratories, administrative offices and an enlarged break area. In 2006, Millipore acquired Serologicals Corporation for $1.4 billion, which itself had previously acquired Cytomyx, one of the industry's largest suppliers of ion channel cell lines (ScripNo 3155, p 14).
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.